Shareholders meeting

05" September, 2026 To, To, The Department of Corporate Services Listing Department BSE Limited National Stock Exchange of India Limited Ground Floor, P. J. Tower, Exchange Plaza, 5% Floor Plot No. C/1, Dalal Street, G. Block Bandra-Kurla Complex, Mumbai-400001 Bandra (E), Mumbai - 400 051 Scrip Code: 524632 NSE Symbol: SHUKRAPHAR Ref: Scrip Code: 524632 Sub.: Submission of Notice of 33" Annual General Meeting (“AGM”) of the Company. Dear Sir/Madam, This is with reference to the above-mentioned subject and in terms of applicable regulations of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we are enclosing herewith a copy of Notice of 33" Annual General Meeting (“AGM”) of the Company scheduled to be held on Monday, September 28, 2026 at 12:00 P.M. (IST) through Video Conferencing (VC). Kindly take the same on your records and acknowledge the receipt thereof. Thanking You, For Shukra Pharmaceuticals Limited DAKSHESH RAMESHCHAND RA SHAH Dakshesh Shah Managing Director DIN: 00561666 Encl.: As above CIN : L24231GJ1993PLC019079 Regd. Office : 3rd Floor, “VEER HOUSE” Opp. WIAA Office, Judges Bunglow Road, Bodakdev, Ahmedabad - 380 054. Factory Add. : 795, Rakanpur, Sola-Santej Road, Ta. Kalol, Dist. Gandhinagar - 382721, Gujarat, India, Ph. : 02764-286317 Annual Report 2025-26 SHUKRA NOTICE (Pursuant to Section 101 of the Companies Act, 2013) NOTICE is hereby given that the 33 (Thirty-Third) Annual General Meeting (“AGM”) of the Members of Shukra Pharmaceuticals Limited will be held on Monday, September 28, 2026 at 12:00 P.M. through Video Conferencing (“VC") / Other Audio-Visual Means (“OAVM"), therefore deemed to be held at the Registered office of the company situated at 03™ Floor, Dev House, Opp. WIAA Office, Judges Bungalows Road, Bodakdev, Ahmedabad-380054, Gujarat, to transact the following business: ORDINARY BUSINES: 1. Consideration and Adoption of the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon: To consider and, if thought fit, to pass with or without modification(s), the following resolution as ordinary Resolution: “RESOLVED THAT the Audited Financial Statements of the Company for the Financial Year ended March 31, 2026 and the Reports of the Board of Directors and Auditor thereon, as circulated to the members, be and are hereby considered and adopted.” 2. Approve and declare final dividend for the financial year 2025-26: To consider and if thoughfitt, to pass with or without modification(s), the following resolution as an Ordinary Resolution: “RESOLVED THAT a final dividend @ 1% of Rs.0.01/- per equity share of Rs.1/- (Rupees One only) each fully paid-up of the Company be and is hereby declared for the financial year ended March 31, 2026 and the same be paid as recommended by the Board of Directors of the Company, out of the profits of the Company for the financial year ended March 31, 2026." 3. Re-appointment of Ms. Sanskruti Patel (DIN: 07108631) as a Director (Executive), who retires by rotation and being eligible, offers herself for re-appointment: To consider and, if thought fit, to pass with or without modification(s), the following resolution as Ordinary Resolution: “RESOLVED THAT pursuant to the provisions of Section 152(6) and other applicable provisions of the Companies Act, 2013, Ms. Sanskruti Patel (DIN: 07108631), who retires by rotation and being eligible offers herself for re-appointment, be and is hereby re-appointed as a Director (Executive) of the Company, liable to retire by rotation.” 4. Regularisation of appointment of Additional Independent Director Mr. Dinesh Chauhan (DIN: 11456530), as an Additional Independent Director of the Company: To consider and, if thought fit, to pass with or without modification(s), the following resolution as Special Resolution: SHUKRA PHARMACEUTICALS LIMITED Annual Report 2025-26 SHUKRA “RESOLVED THAT pursuant to the provisions of Sections 149, 150, 152 and 161 read with Schedule IV and all other applicable provisions, if any, of the Companies Act, 2013 (the 'Act’) and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), and relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations’), and based on the recommendation of the Nomination and Remuneration Committee and approval of the Board of Directors, Mr: Dinesh Chouhan (DIN: 11456530), who was appointed in the capacity of Non- Executive Independent Director of the Company with effect from December 30, 2025 and who holds office up to the date of this Annual General Meeting, and who has submitted a declaration that he meets the criteria of independence as provided in Section 149(6) of the Act and Regulation 16(1)(b) of the SEBI Listing Regulations, be and is hereby appointed and regularised as a Non-Executive Independent Director of the Company, not liable to retire by rotation, to hold office for a term of 5 (five) consecutive years. RESOLVED FURTHER THAT the Board of Directors of the Company (including any Committee thereof) or the Company Secretary be and is hereby authorized to take all such steps, sign and execute all such documents, file the necessary e-form (Form DIR-12) with the Registrar of Companies, make appropriate entries in the statutory registers, and do all such acts, deeds, matters, and things as may be necessary, expedient, or desirable to give full effect to this resolution.” By Order of the Board of Directors Place: Ahmedabad For Shukra Pharmaceuticals Limited Date: 03/09/2026 sd/- Dakshesh Shah Managing Director DIN: 00561666 Registered Office: 3rd floor, Dev House, Opp. WIAA, Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, 380054 CIN: L24231GJ1993PLC019079 Email: info@shukrapharmaceuticals.com Website: www.shukrapharmaceuticals.com NOTES 1. Pursuant to the General Circular No. 03/2025 dated September 22, 2025, 09/2024 dated September 19, 2024, issued by the Ministry of Corporate Affairs (MCA) and circular issued by SEBI vide circular no. SEBI/ HO/ CFD/ CFDPoD-2/ P/ CIR/ 2024/ 133 dated October 3, 2024 (“SEBI Circular”) and other applicable circulars and notifications issued (including any statutory modifications or re-enactment thereof for the time being in force and as amended from time to time, companies are allowed to hold AGM through Video Conferencing (VC) or other audio visual means (OAVM), without the physical presence of members at a common venue. In compliance with the said Circulars, AGM shall be conducted through VC / OAVM. 2. Accordingly, in compliance with the provisions of the Act read with the Circulars, the AGM of the Company is being held through VC /OAVM only. Further, in accordance with the Secretarial Standard- 2 on General Meetings issued by the Institute of Company Secretaries of India (“ICSI") read with SHUKRA PHARMACEUTICALS LIMITED Annual Report 2025-26 SHUKRA Guidance /Clarification dated 15t April, 2020 issued by ICSI, the proceedings of the AGM shall be deemed to be conducted at the Registered Office of the Company which shall be the deemed Venue of the AGM. 3. Pursuantto the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxtyo attend and cast vote for the members is not available for this EGM/AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the AGM through VC/OAVM and participate there at and cast their votes through e-voting. 4. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by followitnhge procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available. This will not include large Shareholders (Shareholders holding 2% or more sha [Showing first 8,000 characters — download PDF for full document]